FIGURE

Fig. 6

ID

ZDB-FIG-210119-16

Publication

El-Sahli et al., 2021 - A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature

Other Figures

All Figure Page

Back to All Figure Page

Fig. 6

Triple drugs co-encapsulated in one NP stopped TNBC PDX tumor growth in vivo.

A Schematic showing the development of a triple-drug NP system co-encapsulating CA4, paclitaxel, and verteporfin. B Viability analysis using an MTT assay after 120-hr treatment with empty-NP (E), paclitaxel-NP (P-NP) + verteporfin-NP (V-NP) + combretastatin-NP (C-NP), or PVC-NP at a 1:2:1 ratio. Drug-NPs were added at 0 and 72 hr. Three drugs co-encapsulated into NP showed better efficacy than combination of individual drug-NPs. C PDX (HCI-002) tumor fragments were engrafted into the mammary fat pads of athymic mice and treated with either control (empty-NP), or PVC-NP (1 mg/kg of paclitaxel and 2 mg/kg verteporfin, 1 mg/kg CA4 co-encapsulated in NP) every 2 days for 20 days. Data are expressed as mean ± SEM, n = 3, *P < 0.05, **P < 0.01, ***P < 0.001.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cell Death Dis.